Announcements Trials
Browse Landscape

Status

Recruiting 141Active not recruiting 66Completed 54Not yet recruiting 28Terminated 27Withdrawn 5Enrolling by invitation 4Suspended 1No longer available 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Melanoma 3Lung Neoplasms 3Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Glioblastoma 2Wilms Tumor 1Uterine Neoplasms 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pinealoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasms by Site 1Meningeal Neoplasms 1

Interventions

revumenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Leukemia × 1 year × Clear all
NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡